Conditional disruption of interactions between Gαi2 and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury
BMC Pharmacology and Toxicology volume 15, Article number: 29 (2014)
Regulator of G protein signaling (RGS) proteins suppress G protein coupled receptor signaling by catalyzing the hydrolysis of Gα-bound guanine nucleotide triphosphate. Transgenic mice in which RGS-mediated regulation of Gαi2 is lost (RGS insensitive Gαi2 G184S) exhibit beneficial (protection against ischemic injury) and detrimental (enhanced fibrosis) cardiac phenotypes. This mouse model has revealed the physiological significance of RGS/Gαi2 interactions. Previous studies of the Gαi2 G184S mutation used mice that express this mutant protein throughout their lives. Thus, it is unclear whether these phenotypes result from chronic or acute Gαi2 G184S expression. We addressed this issue by developing mice that conditionally express Gαi2 G184S.
Mice that conditionally express RGS insensitive Gαi2 G184S were generated using a floxed minigene strategy. Conditional expression of Gαi2 G184S was characterized by reverse transcription polymerase chain reaction and by enhancement of agonist-induced inhibition of cAMP production in isolated cardiac fibroblasts. The impact of conditional RGS insensitive Gαi2 G184S expression on ischemic injury was assessed by measuring contractile recovery and infarct sizes in isolated hearts subjected to 30 min ischemia and 2 hours reperfusion.
We demonstrate tamoxifen-dependent expression of Gαi2 G184S, enhanced inhibition of cAMP production, and cardioprotection from ischemic injury in hearts conditionally expressing Gαi2 G184S. Thus the cardioprotective phenotype previously reported in mice expressing Gαi2 G184S does not require embryonic or chronic Gαi2 G184S expression. Rather, cardioprotection occurs following acute (days rather than months) expression of Gαi2 G184S.
These data suggest that RGS proteins might provide new therapeutic targets to protect the heart from ischemic injury. We anticipate that this model will be valuable for understanding the time course (chronic versus acute) and mechanisms of other phenotypic changes that occur following disruption of interactions between Gαi2 and RGS proteins.
G protein coupled receptor signaling is mediated by four major families of G proteins (Gαs, Gαi/o, Gαq, and Gα12). Gαi coupled receptors play important roles in regulating inflammation, cardiovascular function, endocrine signaling, drug abuse, and anxiety/depression – related behaviors [1–5]. Three different Gαi- isoforms (Gαi1, Gαi2, Gαi3) have been cloned and characterized. Gαi/o-coupled responses can be distinguished from responses mediated by other families of G proteins by their sensitivity to pertussis toxin, but the in vivo roles of individual Gαi/o isoforms remain obscure.
Signaling through Gαi is suppressed by regulator of G protein signaling (RGS) proteins which terminate Gαi signaling by accelerating the hydrolysis of Gα-bound guanine nucleotide triphosphate (GTP) [6, 7]. More than 20 different RGS proteins have been identified. However identifying the physiological roles of individual RGS proteins through selective pharmacological inhibition is not yet possible. Knockout mouse models in which individual RGS proteins have been genetically deleted have been useful in identifying the functions of some RGS proteins, but this approach is complicated by the potential for compensation of the lost RGS protein by other RGS proteins that may have redundant functions. Consequently, we have exploited a mutation in Gαi2 (Gαi2 G184S) that blocks RGS binding and activity . This allows us to define the functions of this individual Gαi-isoform and to explore the physiological roles of interactions between Gαi2 and endogenous RGS proteins [8, 9]. Knock-in mice expressing Gαi2 G184S show enhanced receptor-dependent signaling through Gαi2[8, 9], and they exhibit a number of interesting cardiac phenotype changes including enhanced carbachol-induced bradycardia, enhanced isoproterenol-induced cardiac fibrosis, and premature death in a dilated cardiomyopathy model [8–12]. Hearts from both homozygous and heterozygous Gαi2 G184S mutant mice also exhibit smaller infarcts and better recovery of cardiac contractile function following an ischemic insult . Genetic disruption of interactions between Gαi2 and endogenous RGS proteins also produces several noncardiac phenotypic changes including antidepressant-like behavior , resistance to high fat diet-induced weight gain, decreased body fat, and protection from the development of insulin resistance .
One limitation of this transgenic model is that the Gαi2 G184S mutation is chronically expressed throughout the prenatal and postnatal life of the animal. Thus, it is unclear whether the phenotypes that have been reported result from changes during embryological development and whether the phenotypes require chronic or only acute disruption of interactions between Gαi2 and endogenous RGS proteins. In the present study, we addressed this issue by creating a conditional knock-in mouse model that conditionally expresses RGS insensitive Gαi2 G184S. This study focused on the ability of acute Gαi2 G184S expression to protect the heart from ischemic injury.
All protocols and procedures were approved by the University Committee on Use and Care of Animals at the University of Michigan and by the Animal Care and Use Committee of Ohio Northern University. Experimental procedures and animal husbandry were conducted in accordance with NIH guidelines. Animals were housed in a specific pathogen free facility with a 12 hour: 12 hour light: dark cycle and free access to food and water. Mice expressing RGS-insensitive Gαi2 G184S were generated by a “floxed minigene” strategy [15, 16]. The targeting construct to create the conditional knock-in of the G184S mutation at Gαi2 (Figure 1A) was generated from a 129 BAC library in a manner similar to that previously described for the conventional Gαi2 G184S knock-in mutant mice . Elements included: a 6.4 kb 5’ homology arm containing the endogenous Gnai2 sequence encompassing exons 2 to 4, a minigene version of the wild type Gnai2 gene composed of the fused exons 5 to 8, intron 8 and exon 9 (this Gnai2 wild-type minigene was flanked with loxP sites allowing its deletion under the action of the Cre recombinase), the mutated exon 5 containing the G184S mutation (GGGC to TAGT mutation in position 85 in exon 5), a neo selection cassette flanked with FRT sites allowing its deletion under the Flp recombinase action, and a 2.4 kb 3’ homology arm containing the endogenous Gnai2 sequence encompassing exons 6 to 9 and sequence located downstream of the gene. In addition, AflII and SacI restriction sites were inserted in the 5’ homology arm at the BstEII site between Exon 4 and the 5’ loxP site to be used for Southern blot analysis of the targeted ES cells. A Thymidine Kinase (TK) negative selection marker was inserted upstream of the 5’ homology arm. ES cells (5 × 106 cells - SV129 strain) were electroporated (GenOway; Lyon, France) with 40 μg of linearized plasmid and selection started 48 hours later with 200 ug/ml of G418 followed by selection in GANIX to enhance the likelihood of homologous recombination. Targeted cells were identified by 3’ genomic PCR. Of the 23 positive clones, five also showed the appropriate presence of the AflII/SacI restriction site on 5’ PCR. All five were confirmed by 5’ and 3’ Southern Blot analysis (13.0 kb EcoNI fragment and 11.5 kb AflII fragment, respectively) (GenOway; Lyon, France).
Three independent embryonic stem (ES) cell lines with normal karyotype were used for blastocyst injection into C57BL/6J host blastocysts. Highly chimeric males were bred to C57BL/6J female mice and F1 agouti offspring mice were genotyped by PCR and Southern blot hybridization to validate germline transmission (GenOway; Lyon, France). To delete the FRT-flanked neo gene, offspring showing the presence of the Gαi2 +/fl-neo-G184S allele by genomic PCR were crossed against beta-actin FLPe mice (from the University of Michigan Transgenic Animal Model Core). Litters from this cross were analyzed for the presence of the FLP transgene as well as Gαi2 genotypes by genomic PCR. FLP/Gαi2 +/fl-G184S mice lacking the neo cassette were backcrossed onto the C57BL/6J strain to eliminate the FLPe gene. To generate whole-body Gαi2 G184S conditional knock-in mice, transgenic mice carrying the tamoxifen-sensitive, Cre-ERT2 gene driven by the ROSA26 promoter (The Jackson Laboratory; Bar Harbor, ME) were bred with Gαi2 fl-G184S/fl-G184S mice. All mice used in this study have been backcrossed for five generations onto the C57BL/6J strain. They were between 8 – 20 weeks old and the number for each experiment is indicated in the figure legends. Animals were maintained in a specific pathogen-free facility with a 12-h light/dark cycle and fed standard laboratory chow and water ad libitum.
Genomic DNA was isolated from mouse tail using the HotSHOT method  and analyzed in a single PCR reaction using two forward primers A and C (GAGCCCATGTTTCTTAAAGAAGCAAGGATA and TCCCACACCTTAGTGCCACACCT, respectively) and reverse primer B (TGAGGACATGCCTTCCCAACACAAT), which amplify the Gαi2 + (492-bp) and Gαi2 fl-G184S (745-bp) alleles, respectively.
Tamoxifen preparation and treatment
Tamoxifen (Sigma, T5648) was prepared in peanut oil (Sigma, P2144) containing 10% ethanol at a concentration of 60 mg/ml . Daily doses of 50 mg/kg over five days were given by intraperitoneal injection to induce recombination. Control mice were treated with vehicle (90% peanut oil/10% ethanol) alone.
Blood and tissue collection
Blood was withdrawn from the saphenous vein into dipotassium ethylenediamine tetraacetic acid -coated microtubes before the first and 72 hours after the last dose of tamoxifen and then stored at -80˚C until processing for analysis. Mice were euthanized by pentobarbital injection and tissues were quickly removed, snap-frozen in liquid nitrogen, and stored at -80°C until analysis.
Qualitative assessment for recombination, before and after tamoxifen treatment, was performed by polymerase chain reaction (PCR) using genomic DNA isolated from whole blood and tissue samples from genotyped mice carrying one copy of the ROSA Cre-ERT2 gene and the indicated Gαi2 alleles (Gαi2 +/+or Gαi2 G184S ) was amplified by using forward primer A and reverse primer B described above. This PCR reaction generates a 659-bp band only after Cre recombination. PCR reactions for testing genotype and recombination were carried out under the following conditions: 95°C for 5 min, 35 cycles at 95°C, and 64.5°C each for 30 s, followed by extension at 72°C for 1 min and final extension at 72°C for 2 min.
Tissues were dissected and homogenized in a Bullet Blender homogenizer (Next Advance; Averill Park, NY) with RIPA buffer containing protease inhibitors (20 mM Tris-HCl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM β-glycerophospate, 1% Triton X-100, 0.1% SDS, Complete protease inhibitor cocktail (Roche; Pleasanton, CA). Protein concentrations were measured using the BCA Protein Assay kit (Thermo Fisher Scientific; Rockford, IL). Eighty micrograms of protein were separated on a denaturing 12% SDS–PAGE gel and transferred to PVDF membrane. The membranes were washed, blocked (5% milk in PBS-T), and incubated in the appropriate antibodies overnight at 4°C. Antibodies for Western blot analysis: rabbit anti-Gαi2 (a gift from Dr. Susanne Mumby, University of Texas Southwestern Medical Center) at a dilution of 1:1000 and mouse anti-GAPDH (Cell Signaling Technology, Danvers, MA), as loading control, at a dilution of 1:5000. Secondary antibodies were horseradish peroxidase conjugated. Visualization of the protein bands was done using the Super Signal West Pico chemiluminescent substrate (Thermo Fisher Scientific, Rockford, IL). Films were scanned and quantified using Image J software (NIH, Bethesda, MD). All samples were normalized with GAPDH as a loading control and the amount of Gαi2 protein in wild type tissue was set to 100%.
Allele ratio conversion
RNA was isolated from whole blood, heart, brain, and kidney using a commercial kit (Qiagen, Valencia, CA), and reverse transcription was carried out using Reverse Transcription reagents (Applied Biosystems). PCR was performed using a set of primers that amplify a 442–base pair segment of Gαi2 cDNA including both wildtype and Gαi2 G184S. The primers used were CCAGCGTGCGGATGATGCC and GATGAGGAGATGAACCGCATGCAT. The cDNA PCR products obtained for each sample were purified (Qiagen, Valencia, CA), and directly sequenced on an ABI 3730XL using the forward primer used for amplification of Gαi2 in PCR. The allelic expression ratio of mutant Gαi2 G184S to wildtype Gαi2 in mice was determined from the chromatogram peak heights of the bases differentiating between the Gαi2 G184S mutant and wildtype Gαi2 alleles. Peak heights were determined using Image J software and mutant allele expression was calculated using the formula: % mutant allele expression = (T + A + T-peak heights)/((T + A + T-peak heights) + (G + G + C-peak heights)) X 100. If any of the peaks of the mutant or the wild type sequence were not detected in the chromatogram the sample was considered 100% wild type or 100% mutant, respectively.
Adult cardiac fibroblast culture
Adult cardiac fibroblasts (ACF) were isolated from mice as previously described [12, 18]. Hearts were quickly isolated, placed in ice-cold perfusion buffer, and then perfused via an aortic cannula for 4 min with calcium-free perfusion buffer (NaCl, 113 mM; KCl, 4.7 mM; MgSO4-7H2O, 1.2 mM; Na2HPO4, 0.6 mM; KH2PO4, 0.6 mM; phenol red, 0.032 mM; HEPES, 10 mM; NaHCO3, 12 mM; KHCO3, 10 mM; taurine, 30 mM; glucose, 5.5 mM; and butanedione monoxime, 10 mM, pH 7.46). Hearts were then perfused for 8 min with the same buffer containing 0.5 mg/ml collagenase II (Worthington Biochemicals, Lakewood) and 1.25 μM CaCl2. Hearts were removed from the apparatus and the ventricles were suspended in perfusion buffer with collagenase and 1.25 μM CaCl2. The tissue was disrupted with fine forceps and by gentle pipetting. Cells were transferred to buffer containing 1.25 μM CaCl2 and 10% serum to stop the digestion. Samples were centrifuged at 180×g for 1 min to remove debris and myocytes. The remaining suspended fibroblasts were centrifuged at 300 × g for 10 min, then resuspended in phosphate buffered saline, centrifuged again, the supernatant was discarded, and the final cell pellet was resuspended in Dulbecco's modified Eagle’s medium supplemented with 1% penicillin/streptomycin, insulin/transferrin/selenium (ITS from Sigma) 1X, and 10% fetal bovine serum.
cAMP production in adult cardiac fibroblasts
The effect of lysophosphatidic acid (LPA) on 3´,5´ cyclic adenosine monophosphate (cAMP) production in ACF was determined in 384-well plates using the Lance Ultra cAMP kit (PerkinElmer; Waltham, MA). Briefly, ACF (passage 2) were added at 1,000 cells per well and cAMP accumulation was initiated by adding stimulation buffer containing 0.5 mM isobutyl-1-methylxanthine and 10 μM forskolin with the indicated concentrations of LPA. After 30 min at room temperature, the reaction was stopped by lysing the cells using the buffer supplied with the PerkinElmer kit. Time-resolved fluorescence was measured with a Synergy 2 (BioTek; Winooski, VT) microplate reader.
Langendorff isolated heart preparation and infarct size measurement
Mice were treated with tamoxifen or vehicle for 5 days as described above. Fourteen days after the first injection, mice were anesthetized and heparinized by a single injection containing pentobarbital (100 mg/kg) and heparin (150 mg/kg). Hearts were immediately excised and cannulated while bathed in ice-cold Krebs solution. Krebs solution was perfused through the aortic cannula at a constant pressure of 75 mmHg. Hearts were subjected to 30 minutes of ischemia and 2 hours reperfusion as previously described . Contractile function of the left ventricle was continuously measured using an intraventricular balloon and infarct size was measured by triphenyltetrazolium chloride staining as described previously .
Data were analyzed using one-way or two-way analysis of variance, followed by a Bonferroni’s post test or a Tukey’s post test when appropriate. GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA) was used for statistical analysis.
To implement a conditional knock-in strategy, a replacement-type minigene targeting vector was used to modify the Gnai2 gene as depicted in Figure 1A-C. This construct was designed to (1) flank an exon 5 through 9 minigene with loxP recombination recognition sites, (2) insert a neomycin selection cassette that was flanked by FRT recombination sites downstream of the floxed wild type Gαi2 coding and regulatory sequences, and (3) replace the wildtype genomic exon 5 with the G184S mutant version followed by the remainder of the wildtype Gαi2 sequence in the normal genomic context. Because of size constraints on the cloning vector used to create the targeting construct, exons 5 through 8 were fused and introns 5-7 were deleted. Intron 8 and non-coding exon 9 were retained due to the presence of regulatory elements. The knock-in mutation was introduced into the genomic exon 5 to change the codon for glycine 184 to serine (Figure 1A). Following electroporation of the targeting construct into embryonic stem cells, G418-resistant ES cell clones were screened for gene targeting by PCR and confirmed by Southern blot analysis. Blots were hybridized to 5’ and 3’ probes. After genomic DNA digestion with EcoNI, the 5’ probe hybridized with a 13.0 kb fragment generated from a recombinant Gai2 G184S allele (Figure 1D). This was confirmed by blotting with a 3’ probe after genomic DNA digestion with AflII. This probe hybridized to a 7.9 kb fragment from the wild type Gai2 allele and an 11.5 kb fragment from a Gai2 G184S allele (Figure 1E). One ES cell clone was not targeted (lane 5) and four clones were correctly targeted (lanes 1 to 4). Three targeted ES cell clones with normal karyotype were used to produce germline-competent chimeric mice using standard techniques. After FLP recombinase crosses, mice that were heterozygous for the targeted locus without the neomycin cassette (fl-G184S allele) were subsequently backcrossed with C57BL/6J mice to eliminate the beta-actin FLP transgene. Figure 2A shows representative results from the PCR screening used to select mice with the desired genotype.
To demonstrate a global, time-dependent, and Cre-mediated conversion of the conditional allele (fl-G184S) to the RGS insensitive allele (G184S), we crossed mice that were homozygous for the fl-G184S allele (Gαi2 fl-G184S/fl-G184S) mice with a tamoxifen-dependent Cre general deleter mouse line [19–21]. This line expresses a tamoxifen-sensitive Cre (Cre-ERT2) from the ROSA26 locus (Figure 1C). When tamoxifen is administered, its metabolite 4-OH tamoxifen binds to the Cre-ERT2 which translocates to the nucleus facilitating recombination of genomic loxP sites. As shown in Figure 2B, this removes the E5-9 minigene and positions mutant Exon 5 (E5*) in the normal Gnai2 genomic context to express the mutant Gαi2 G184S protein. Gαi2 fl-G184S/fl-G184S and Cre-ERT2/Gαi2 fl-G184S/fl-G184S mice are viable and do not show any gross developmental abnormalities.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis was used to amplify a 442-bp cDNA product expressed from the Gnai2 gene to assess the ratio of mutant to wildtype Gαi2 RNA expression. Only the Cre-ERT2/Gαi2 +/fl-G184S, or Cre-ERT2/Gαi2 fl-G184S/fl-G184S mice express mutant mRNA after tamoxifen treatment. Gαi2-specific PCR products from each genotype were sequenced (Figure 3A). This analysis confirmed that the Gαi2 cDNA sequence from Gαi2 fl-G184S/fl-G184S mice prior to tamoxifen treatment was identical to the previously published mouse cDNA sequence [22, 23]. In contrast, the Gαi2 cDNA sequence from Cre-ERT2/Gαi2 +/fl-G184S, or Cre-ERT2/Gαi2 fl-G184S/fl-G184S mice revealed the nucleotide changes that were introduced to change the codon for glycine at 184 to serine. Peak heights from the chromatograms were used to quantify the relative amount of mutant mRNA expression in several tissues . In mice that were homozygous for fl-G184S (Gαi2 fl-G184S/fl-G184S), we found 60 – 100% conversion to the mutant sequence in most tissues evaluated (Figure 3B). As expected, heterozygous animals (Gαi2 +/fl-G184S) exhibited lower rates of conversion because they retained one copy of the wildtype allele. The lack of conversion in brain was presumably due to lack of Cre-ERT2 expression in post-mitotic neurons, and low brain penetration by tamoxifen .
Surprisingly, Gαi2 protein expression levels were significantly reduced in several organs (heart, brain, and kidney) isolated from Gαi2 fl-G184S/fl-G184S and Cre-ERT2/Gαi2 fl-G184S/fl-G184S mice compared to Gαi2 +/+control animals that do not express Cre or the Gαi2 G184S mutation (Figure 4). We also assessed whether there were compensatory changes in other G proteins in heart ventricles. We found no detectable levels of Gαo, Gαi1, or Gαi3 in wildtype ventricles nor were they present in Gαi2 fl-G184S/fl-G184S or Cre-ERT2/Gαi2 fl-G184S/fl-G184S ventricles either before or after tamoxifen treatment (data not shown). This is consistent with previous reports that Gαi2 is a predominant Gαi isoform in the myocardium [25, 26].
We previously demonstrated that embryonic fibroblasts from conventional (i.e. non-conditional) Gαi2 G184S knock-in mice have enhanced activity in several biochemical and physiological measures of the Gαi signaling pathway . Thus, we investigated the functional consequences of conditional Gαi2 G184S expression at the cellular level in a cAMP inhibition assay. Adult cardiac fibroblasts from mice treated with tamoxifen (which developed ~90% mutant allele expression, data not shown) were isolated and cultured. cAMP production in these cells was measured following exposure to forskolin (10 μM) and increasing concentrations of lysophosphatidic acid (LPA). Data were compared by two-way ANOVA with genotype and LPA concentration as variables. A significant effect of genotype (P < 0.05) in the inhibition of cAMP production was observed. Bonferroni’s post test revealed that ACF from the conditional knock-in mice (Cre-ERT2/Gαi2) had significantly (P < 0.05) augmented inhibition of cAMP production with the highest concentration of LPA compared to cells from Gαi2 fl-G184S/fl-G184S mice that do not convert to the G184S mutation (Figure 5). These data are consistent with our previous finding that LPA-induced inhibition of adenylate cyclase activity is enhanced in embryonic fibroblasts in the nonconditional Gαi2 G184S model , and they provide evidence that agonist-induced Gαi2 signaling is enhanced in cardiac fibroblasts that conditionally express the Gαi2 G184S allele.
We previously demonstrated that the conventional Gαi2 G184S mutant mice (both heterozygotes and homozygotes) are resistant to ischemia-reperfusion injury . However, it was unclear whether this phenotype resulted from Gαi2 G184S expression during embryonic development or whether the cardioprotective phenotype requires chronic or acute Gαi2 G184S expression. In the present study, we found that ischemia-induced infarct size was significantly decreased in tamoxifen-treated Cre-ERT2/Gαi2 fl-G184S/fl-G184S compared to both vehicle-treated Cre-ERT2/Gαi2 fl-G184S/fl-G184S hearts and tamoxifen-treated Gαi2 fl-G184S/fl-G184S without Cre expression (Figure 6). Consistent with reduced myocardial infarct size (Figure 6), hearts isolated from tamoxifen-treated Cre-ERT2/Gαi2 fl-G184S/fl-G184S exhibited significantly enhanced postischemic recovery of developed pressure compared to hearts isolated from either vehicle-treated Cre-ERT2/Gαi2 fl-G184S/fl-G184S mice or tamoxifen-treated Gαi2 fl-G184S/fl-G184S mice that do not express Cre-ERT2 (Table 1). Postischemic recovery of + dP/dT and –dP/dT were also enhanced in hearts isolated from tamoxifen treated Cre-ERT2/Gαi2 fl-G184S/fl-G184S animals. Postischemic recovery of end diastolic pressure was nominally lower in tamoxifen-treated Cre-ERT2/Gαi2 fl-G184S/fl-G184S compared to the other groups (Table 1). However, this did not reach statistical significance. These data are consistent with our previous report that nonconditional expression of Gαi2 G184S protects the heart from ischemic injury . Importantly, they extend our previous findings by demonstrating that the cardioprotective phenotype does not result from embryonic or chronic expression of Gαi2 G184S. Rather, acute disruption of interactions between Gαi2 and endogenous RGS proteins is sufficient to induce cardioprotection.
We previously described a mouse model in which signaling by Gαi2 was enhanced by introduction of a point mutation (G184S) that blocks negative regulation by RGS proteins . These mice exhibited a number of complex and interesting phenotypes including protection from cardiac ischemia/reperfusion injury . However, it was unclear whether this cardioprotective phenotype resulted from changes in Gαi2 signaling during embryonic development. It was also unknown whether chronic Gαi2 G184S expression was required or whether acute expression was sufficient to protect the heart from ischemic injury. These are important issues because the potential finding that embryonic or chronic expression of Gαi2 G184S is required for cardioprotection would likely preclude the use of pharmacological RGS inhibitors from therapeutic use in the treatment of ischemic heart disease. The present study extends our previous findings by demonstrating that acute (days rather than months) disruption of interactions between Gαi2 and endogenous RGS proteins is sufficient to protect the heart from ischemic injury. These data suggest that RGS proteins might provide novel therapeutic targets to protect the heart from ischemic injury.
Conditional expression of Gαi2 G184S resulted in a 55% reduction in infarct size relative to hearts isolated from tamoxifen-treated mice that did not express Cre-ERT2, and a 65% reduction in infarct size compared to hearts isolated from mice that expressed Cre-ERT2 but were not treated with tamoxifen. By comparison, we previously reported that nonconditional expression of Gαi2 G184S resulted in 41% and 68% reductions in infarct sizes in hearts isolated from mice that were heterozygous or homozygous for the Gαi2 G184S mutation, respectively . Recovery of developed pressure, +dP/dT, and -dP/dT were significantly increased in both models of Gαi2 G184S expression (Table 1 and ). Thus, conditional expression of this mutation produced a cardioprotective phenotype that was similar to the phenotype previously observed in the conventional (nonconditional) Gαi2 G184S knockin model.
Mice expressing the Gαi2 G184S in a nonconditional fashion also exhibit several noncardiac phenotypic differences including: resistance to high fat diet-induced weight gain and resistance to the development of insulin insensitivity, reduced embryonic viability, elevated neutrophil counts, and antidepressant-like behavior [5, 8, 14]. We anticipate that the conditional Gαi2 G184S expression model described here will be helpful in characterizing the temporal requirements (acute versus chronic) of Gαi2 G184S expression for some of these phenotypes. Our finding that tamoxifen produced very little conversion to the Gαi2 G184S mutation in the brain suggests that this model may not be useful for characterizing the anxiolytic or antidepressant-like behavior that has been previously reported in nonconditional Gαi2 G184S mice . On one hand, this represents a significant limitation of this model. However, the observation that the conventional Gαi2 G184S model, but not the conditional Gαi2 G184S model, expresses the G184S mutation in the brain might be useful for elucidating the ability of enhanced Gαi2 signaling in the central nervous system to impact the function of peripheral tissues. The reason for a lack of conversion to the Gαi2 G184S mutation in the brain is unclear. However, other investigators using the Cre-ERT2 system have reported similar results. Seibler et al. confirmed that Cre-ERT2 is expressed in the brain and suggested that the lack of recombination may reflect low local concentrations of 4-hydroxytamoxifen .
The tamoxifen- and Cre-dependent recombination and expression of mutant mRNA meets the criteria planned for the engineered Gnai2 locus: lack of mutant mRNA expression before tamoxifen treatment with good conversion to the G184S mutation after tamoxifen treatment. We did observe reduced Gαi2 protein expression in the heart, kidney, and brain of Gαi2 flG184S/fl-G184S and Cre-ERT2/Gαi2 flG184S/fl-G184S mice relative to wildtype mice that do not express Cre or carry the G184S mutation, suggesting that the loss of introns in the minigene that carries the wildtype sequence and/or the residual LoxP or FLP recombinase (FRT) sites may perturb regulatory and/or splicing elements. However, the observation that LPA-induced inhibition of cAMP production is augmented in cardiac fibroblasts isolated from Cre-ERT2/Gαi2 flG184S/fl-G184S mice (Figure 5) indicates that agonist-induced signaling via Gαi2 is actually increased (relative to fibroblasts that do not express the mutation), despite decreased Gαi2 expression levels. This presumably occurs because the negative regulatory effect of RGS proteins toward Gαi2 is disrupted in these cells. Many different Gαi-coupled receptors are known to protect the heart from ischemia/reperfusion injury. Thus, the finding that conditional expression of Gαi2 G184S produces a cardioprotective phenotype is also consistent with enhanced Gαi2 signaling despite decreased Gαi2 protein expression.
In conclusion, the conditional Gαi2 G184S knock-in model described here permits the disruption of interactions between Gαi2 and endogenous RGS proteins in a time-dependent manner. Our data demonstrate that acute (rather than chronic) disruption of interactions between RGS proteins and Gαi2 is sufficient to protect the heart from ischemic injury. This suggests that the development of chemical inhibitors of RGS proteins or other agents that disrupt interactions between RGS proteins and Gαi2 might provide new therapeutic tools to protect the heart from ischemic injury. In addition, we anticipate that this transgenic mouse model will provide a valuable tool for characterizing the mechanisms by which disruption of RGS protein-Gαi2 interactions confers other phenotypes that have been identified in mice expressing Gαi2 G184S.
Adult cardiac fibroblast
- Gαi2 +/+ :
Wildtype Gαi2 allele
- Gαi2 G184S :
Gαi2 allele with point mutation
Polymerase chain reaction
Regulator of G protein signaling.
Hörnquist CE, Lu X, Rogers-Fani PM, Rudolph U, Shappell S, Birnbaumer L, Harriman GR: G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol. 1997, 158: 1068-1077.
DeGeorge BR, Gao E, Boucher M, Vinge LE, Martini JS, Raake PW, Chuprun JK, Harris DM, Kim GW, Soltys S, Eckhart AD, Koch WJ: Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation. 2008, 117: 1378-1387. 10.1161/CIRCULATIONAHA.107.752618.
Nagata K, Ye C, Jain M, Milstone DS, Liao R, Mortensen RM: Galpha(i2) but not Galpha(i3) is required for muscarinic inhibition of contractility and calcium currents in adult cardiomyocytes. Circ Res. 2000, 87: 903-909. 10.1161/01.RES.87.10.903.
Inoue Y, Yao L, Hopf FW, Fan P, Jiang Z, Bonci A, Diamond I: Nicotine and ethanol activate protein kinase A synergistically via G(i) betagamma subunits in nucleus accumbens/ventral tegmental cocultures: the role of dopamine D(1)/D(2) and adenosine A(2A) receptors. J Pharmacol Exp Ther. 2007, 322: 23-29. 10.1124/jpet.107.120675.
Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM, Huang X, Neubig RR, Traynor JR: RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proc Natl Acad Sci U S A. 2010, 107: 11086-11091. 10.1073/pnas.1000003107.
Kimple AJ, Bosch DE, Giguere PM, Siderovski DP: Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev. 2011, 2011 (63): 728-749.
Sjogren B, Blazer LL, Neubig RR: Regulators of G protein signaling proteins as targetes for drug discovery. Prog Mol Biol Transl Sci. 2010, 91: 81-119.
Huang X, Fu Y, Charbeneau RA, Saunders TL, Taylor DK, Hankenson KD, Russell MW, D’Alecy LG, Neubig RR: Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele. Mol Cell Biol. 2006, 26: 6870-6879. 10.1128/MCB.00314-06.
Fu Y, Zhong H, Nanamori M, Mortensen RM, Huang X, Lan K, Neubig RR: RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. Methods Enzymol. 2004, 389: 229-243.
Fu Y, Huang X, Piao L, Lopatin AN, Neubig RR: Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. Am J Physiol Heart Circ Physiol. 2007, 292: H2532-H2539. 10.1152/ajpheart.01391.2006.
Fu Y, Huang X, Zhong H, Mortensen RM, D’Alecy LG, Neubig RR: Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects. Circ Res. 2006, 98: 659-666. 10.1161/01.RES.0000207497.50477.60.
Kaur K, Parra S, Chen R, Charbeneau RA, Wade SM, Jay PY, Neubig RR: Galpha(i2) signaling: friend or foe in cardiac injury and heart failure? Naunyn Schmiedebergs. Arch Pharmacol. 2012, 38: 443-453.
Waterson RE, Thompson CG, Mabe NW, Kaur K, Talbot JN, Neubig RR, Rorabaugh BR: Galpha(i2)-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart. Cardiovasc Res. 2011, 91: 45-52. 10.1093/cvr/cvr054.
Huang X, Charbeneau RA, Fu Y, Kaur K, Gerin I, MacDougald OA, Neubig RR: Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gnai2 allele. Diabetes. 2008, 57: 77-85.
Xin HB, Deng KY, Shui B, Qu S, Sun Q, Lee J, Greene KS, Wilson J, Yu Y, Feldman M, Kotlikoff MI: Gene trap and gene inversion methods for conditional gene inactivation in the mouse. Nucleic Acids Res. 2005, 33: e14-10.1093/nar/gni016.
Wingate AD, Martin KJ, Hunter C, Carr JM, Clacher C, Arthur JS: Generation of a conditional CREB Ser133Ala knockin mouse. Genesis. 2009, 47: 688-696. 10.1002/dvg.20548.
Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML: Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques. 2000, 29: 52-54.
O’Connell TD, Rodrigo MC: Simpson PC (2007) Isolation and culture of adult mouse cardiac myocytes. Methods Mol Biol. 2007, 357: 271-296.
Anastassiadis K, Glaser S, Kranz A, Berhardt K, Stewart AF: A practical summary of site-specific recombination, conditional mutagenesis, and tamoxifen induction of CreERT2. Methods Enzymol. 2010, 2010 (477): 109-123.
Hameyer D, Loonstra A, Eshkind L, Schmitt S, Antunes C, Groen A, Bindels E, Jonkers J, Krimpenfort P, Meuwissen R, Rijswijk L, Bex A, Berns A, Bockamp E: Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics. 2007, 31: 32-41. 10.1152/physiolgenomics.00019.2007.
Rodríguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R, Stewart AF, Dymecki SM: High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 2000, 25: 139-140. 10.1038/75973.
Strathmann M, Wilkie TM: Simon MI (1989) Diversity of the G-protein family: sequences from five additional alpha subunits in the mouse. Proc Natl Acad Sci U S A. 1989, 86: 7407-7409. 10.1073/pnas.86.19.7407.
Sullivan KA, Liao YC, Alborzi A, Beiderman B, Chang FH, Masters SB, Levinson AD, Bourne HR: Inhibitory and stimulatory G proteins of adenylate cyclase: cDNA and amino acid sequences of the alpha chains. Proc Natl Acad Sci U S A. 1986, 83: 6687-6691. 10.1073/pnas.83.18.6687.
Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG: Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010, 115: 3589-3597. 10.1182/blood-2009-04-215848.
Dizayee S, Kaestner S, Kuck F, Hein P, Klein C, Piekorz RP, Meszaros J, Matthes J, Nürnberg B, Herzig S: Gαi2- and Gαi3-specific regulation of voltage-dependent L-type calcium channels in cardiomyocytes. PLoS One. 2011, 6: e24979-10.1371/journal.pone.0024979.
Foerster K, Groner F, Matthes J, Koch WJ, Birnbaumer L, Herzig S: Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through beta 2-adrenoceptors. Proc Natl Acad Sci U S A. 2003, 100: 14475-14480. 10.1073/pnas.1936026100.
Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T, Rode A, Heimann C, Faust N, Kauselmann G, Schoor M, Jaenisch R, Rajewsky K, Kuhn R, Schwenk F: Rapid generation of inducible mouse mutants. Nucleic Acids Res. 2003, 31: e11-e13. 10.1093/nar/gng01.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/2050-6511/15/29/prepub
This work was supported by NIH R01-GM39561 (R.R.N) and was also supported in part by the Michigan Diabetes, Research, and Training Center (NIH P60 DK20572), and the University of Michigan Comprehensive Cancer Center (NIH P30 CA046592). We thank Dr. Susanne Mumby (UT Southwestern Medical Center) for the specific Gαi2 antibody, Dr. Thomas Gettys for the specific Gαi1 and Gαi3 antibodies, Dr. Thomas Saunders and Elizabeth Hughes (University of Michigan Transgenic Animal Model Core) for providing the FLPe mice and for the ES cells electroporation, respectively. We also thank Dr. Sally Camper, Dr. Thomas Saunders, and the staff at the University of Michigan Transgenic Animal Model Core and the staff at GenOway (Lyon, France) for helpful suggestions regarding the generation of the conditional knock-in mice.
The authors have no financial or nonfinancial competing interests.
RRN, SP, and XH conceived and designed the experiments. SP, BRR, KK, RAC, SMW, and XH performed the experiments. SP, RRN, and BRR analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Parra, S., Huang, X., Charbeneau, R.A. et al. Conditional disruption of interactions between Gαi2 and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury. BMC Pharmacol Toxicol 15, 29 (2014). https://doi.org/10.1186/2050-6511-15-29